Transforming Fibrosis Treatment With Precision Matrix Targeting
Fibrosis contributes to over 45% of deaths in the developed world. By using evolutionarily optimized matrix targeting peptides, Tandem Tx overcomes the extracellular matrix barrier to unlock the previously inaccessible multidimensional druggable space. Using a deep understanding of matrix mechanobiology and its relation to disease progression, the ETH-spinoff is developing a pipeline of conditionally targeted, efficacious and safer therapies to treat fibrotic diseases.